Bispecific antibodies are engineered to simultaneously bind two different antigens. They can be used to tailor the binding dynamics and effector functions of antibodies to specific cell types. We are developing two bispecific antibodies based on highly innovative strategies to combat tumor escape mechanisms.
AGEN1223 is designed to selectively deplete immunosuppressive T regulatory cells from the tumor microenvironment. This agent takes advantage of co-expression of the target antigens specifically on tumor-infiltrating T regulatory cells. In contrast to other strategies targeting T regulatory cells, AGEN1223 is expected to spare important immune regulatory peripheral Tregs and cancer-fighting effector T cells.
AGEN1223 is advancing in a clinical trial against solid tumors.
Latest Clinical Trials
Enrolling in solid tumors
Phase 1 study to evaluate the safety, tolerability, PK, and pharmacodynamic profiles of AGEN1223 and to assess the maximum tolerated dose (MTD) in subjects with advanced solid tumors